

20 July 2023

Multiple Myeloma

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

There were 115 Adult Myeloma patients treated for the period 1st January to 30th June 2023.

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- Belantamab Mafodotin [Blenrep]
- Bortezomib [Velcade] monotherapy or with dexamethasone
- Bortezomib, thalidomide and dexamethasone [VTD]
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
- Carfilzomib [Kyprolis] and dexamethasone
- Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
- Daratumumab [Darzalex] monotherapy
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
- Elranatamab
- Idecabtagene vicleucel [Abecma]
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
- Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
- Lenalidomide [Revlmid] monotherapy
- Lenalidomide [Revlmid] and dexamethasone
- Pomalidomide [Imnovid] and dexamethasone
- Selinexor and dexamethasone
- Talquetamab
- Teclistamab [Tecvayli]
- Any other systemic anti-cancer therapy

Belfast Trust does not hold this information centrally. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours. This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this (element of the) request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.